Disease Immune Response Science 
Science Daily: Pharmacology News
JUNE 19, 2025
Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response with just one dose. By combining two immune-boosting adjuvants alum and SMNP the vaccine lingers in lymph nodes for nearly a month, encouraging the body to produce a vast array of antibodies.
Drug Target Review
JULY 21, 2025
Disorders such as Alzheimer’s disease , primary glioblastoma and amyotrophic lateral sclerosis (ALS) all affect the CNS and are considered fatal, while more common conditions, including depression , strokes and epilepsy , require long-term treatments. Hundreds of life-altering conditions attack the central nervous system (CNS).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
JULY 31, 2025
Together, these innovations finetuned in biopharma are elevating the reliability and interpretability of antibody-based detection methods, making them more robust tools for both basic and translational science. Researchers can more closely mimic intended therapeutic mechanisms without triggering unintended immune responses in model animals.
Drug Target Review
MAY 23, 2025
As the biotech sector races to improve the tolerability of these revolutionary treatments, Poolbeg Pharma has a novel solution: an oral therapy, POLB 001, to block the development of CRS, by limiting inflammation without affecting the anti-cancer immune responses that are vital for effective immunotherapies.
Drug Target Review
JULY 18, 2025
These CCR8+ Tregs are known to suppress immune responses in the tumour microenvironment (TME), allowing cancers to grow unchecked. “DT-7012 This opens the door for a disease-modifying approach both as a monotherapy and in combination, expanding treatment options and offering new hope to millions of patients.”
The Pharma Data
JUNE 25, 2025
The designation is reserved for medicines aimed at treating rare diseases that affect fewer than 200,000 people annually in the United States. The company has emphasized that its investigational therapies are designed not only to control symptoms but to alter the course of disease.
Drug Target Review
APRIL 7, 2025
The challenge of GPCR drug discovery G protein-coupled receptors (GPCRs) are one of the most desirable and challenging target classes in drug discovery, as their mutation can lead to a wide range of diseases such as cancer, cardiovascular disorders and neurological conditions.
Expert insights. Personalized for you.
Let's personalize your content